Journal
PATHOLOGY RESEARCH AND PRACTICE
Volume 239, Issue -, Pages -Publisher
ELSEVIER GMBH
DOI: 10.1016/j.prp.2022.154163
Keywords
IDH -mutant astrocytoma; CDKN2A; B; NTRK2; NGS-custom panel
Categories
Ask authors/readers for more resources
This study reported a case of IDH-mutant astrocytoma that recurred with aggressive behavior and increased malignancy, showing genomic evolution during tumor recurrence. The recurrent tumors carried NTRK fusion and CDKN2A/B homozygous deletion, which may promote high-grade transformation and indicate an unfavorable prognosis for IDH-mutant astrocytoma.
We reported a case of molecularly defined isocitrate dehydrogenase (IDH)-mutant astrocytoma that recurred twice with aggressive behavior and increased anaplastic morphology. Primary and recurrent tumors were analyzed using custom-made DNA-based cancer gene and RNA-based fusion panels for next-generation sequencing (NGS). NGS analyses revealed that recurrent astrocytoma, in addition to IDH1 and tumor protein 53 mutations detected in the primary lesion, harbored cyclin-dependent kinase inhibitor (CDKN) 2 A/B homozygous deletion and neurotrophic tropomyosin receptor kinase 2 (NTRK2) fusion genes that consisted of golgin A1- and cyclin-dependent kinase 5 regulatory subunit associated protein 2-NTRK2 fusions. Anaplasia and necrosis were observed in the recurrent tumors, but not in the primary lesion. Therefore, the integrative diagnosis was primary IDH-mutant astrocytoma grade 2 and recurrent IDH-mutant astrocytoma grade 4 with NTRK2 fusions. This is a worthwhile report describing a case of IDH-mutant astrocytoma that showed genomic evolution during tumor recurrence. Our report suggests that NTRK fusion and CDKN2A/B homozygous deletion promote high-grade transformation and indicate an unfavorable prognosis of IDH-mutant astrocytoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available